By the late 2000s, Michele Brooks is taking the lead on a new generation of Life Sciences work. Her early signature commission is Anika Therapeutics in 2007, the first major project of what will become a twenty-year stewardship of the sector. The handoff from Randy Lewis to Michele is the firm’s first deliberate generational transition, and a model for the ones that follow.